

**PHARMACOLOGY**  
**PAPER-I**

PHARMA/D/17/34/I

Time: 3 hours  
Max. Marks: 100

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space
- Answer all the parts of a single question together.
- Start the question to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. a) Write the in-vitro and animal toxicity tests required for new drug development. 5+5
  - b) What are preclinical evaluation methods for potential antiepileptic new chemical entity?
2. a) What are the ethical and regulatory issues in use of animals in biomedical research? 5+5
  - b) Composition and functions of Institutional Ethics Committee for research in human subjects.
3. a) Methods of Pharmacovigilance with their advantages and limitations 5+5
  - b) Pharmacogenomics interlink with pharmacovigilance, giving examples.
4. a) What are the inclusion and exclusion criteria of papers in meta analysis. What is the advantage of meta analysis? 5+5
  - b) What are the methods and implications of drug utilization studies?
5. a) Difference between partial agonist and inverse agonist giving suitable examples. 4+6
  - b) Define median lethal dose and median effective dose and their importance in Therapeutics.
6. a) Define bioavailability and how it is determined. Give suitable examples. 5+5
  - b) What is the difference between pharmaceutical equivalent and therapeutic equivalent? Give suitable equivalence.
7. a) Role of Placebo in clinical trials. 5+5
  - b) Mention advantages and disadvantages of fixed dose combination.

- |     |  |     |
|-----|--|-----|
| 8.  | a) Principles and steps in preparing National List of Essential Medicine (NLEM)            | 5+5 |
|     | b) Potential uses of NLEM in rational therapeutics.  |     |
| 9.  | a) Define plasma half life of a drug and its clinical significance with suitable examples. | 5+5 |
|     | b) Nanotechnology in drug delivery system.   |     |
| 10. | a) Define drug dependence and its mechanisms.  | 5+5 |
|     | b) Principles of treatment of drug dependence with suitable examples.                      |     |